Systemic lupus erythematosus is commonly associated with early onset cardiovascular disease and is often associated with hyperlipidaemia. This review examines the evidence for an increased prevalence of both CHD and hyperlipidaemia in SLE and mechanisms by which autoimmunity in SLE could accelerate the progression of atheroma. It postulates how lipid lowering therapies used in cardiological disease might help reduce the incidence of CHD in SLE.
Ward MM , Pyun E , Studenski S . Causes of death in systemic lupus erythematosus . Arthritis Rheum1995; 38: 1492 — 1499 .
3.
Harisdangkul V , Nilganuwonge S , Rockhold LV . Cause of death in systemic lupus erythematosus: a pattern based on age . Southern Med J1987; 80: 1249 — 1253 .
4.
Shah N , Khamashta MA , Atsumi T , Hughes GRV . Outcome of patients with anti-cardiolipin antibodies: a 10 year follow-up of 52 patients . Lupusl998; 7: 3—6 .
5.
Sturfeld G , Eskilsson J , Nived O et al. Cardiovascular disease in systemic lupus erythematosus . Medicine1992; 71: 216 — 222 .
6.
del Rio A , Vazquez JJ , Sobrino JA et al. Myocardial involvement in systemic lupus erythematosus . Chest1978; 74: 414 — 416 .
7.
Bulkley BH , Roberts WC . The heart in systemic lupus erythematosus and changes induced in it by corticosteroid therapy: a study in 36 necropsy patients . Am J Med1975; 58: 243 — 264 .
8.
Hosenpu JD , Montanaro A , Hart MV et al. Myocardial perfusion abnormalities in asymptomatic patients with sytemic lupus erythematosus . Am J Med1984; 77: 286 — 292 .
9.
Farhey Y , Hess V . Accelerated atherosclerosis and coronary disease in SLE . Lupus1997; 6: 572 — 577 .
10.
Petri M , Perez-Guthann S , Spence D , Hochberg MC . Risk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med1992; 93: 513 — 519 .
11.
Zuckerman E , Roubi E , Shiran A et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients; a controlled prospective study . Am J Med1996; 101: 81— 386 .
12.
Manzi S , Selzer F , Sutton-Tyrell K et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus . Arthritis Rheum1999; 42: 51-60 .
13.
Manzi S , Meilahn EN , Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study . Am J Epidemiol1997; 145: 408 — 115 .
14.
O'Leary DH , Polak JF , Kronmal RPH et al. Carotid-artery intima and media thickness as a risk factor for myocardial infraction and stroke in older adults . New Engl J Med1999; 340: 14 — 22 .
15.
Celermajer DS . Non-invasive detection of atherosclerosis . New Engl J Med1998; 339: 2014 — 2015 .
16.
McDonald J , Stewart J , Urowitz , Gladman DD . Peripheral vascular disease in patients with systemic lupus erythematosus . Am J Med1992; 93: 513 — 519 .
17.
Fligelstone LI , Cachia PG , Ralis H et al. Lupus anti-coagulant in patients with peripheral vascular disease: a prospective study . Eur J Endovasc Surg1995; 9: 277 — 283 .
18.
Simon Broome Register Group . Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management . Atherosclerosis1999; 142: 105 — 112 .
19.
O'Brien KD , Chait A . Biology of the arterial wall in atherogenesis . Med Clin North Am1994; 78: 47 — 67 .
20.
Wierzbicki AS . Role of lipid lowering in transplantation . Intl Clin Practice1999; 53: 54 — 59 .
21.
Kobashigawa JA , Kasiske BL . Hyperlipidaemia in solid organ transplants . Transplantation1997; 63: 331 — 338 .
22.
Arnadottir M , Berg A-L . Treatment of hyperlipidaemia in renal transplant recipients . Transplantation1997; 63: 339 — 345 .
O'Brien KD , Reichenbach DD , Marcovina SM et al. Apolipoproteins B, (a) and E accumulate in the morphologically early lesion of `degenerative' valvular aortic stenosis . Arterioscler Thromb Vasc Biol1996; 16: 523 — 532 .
25.
Wierzbicki AS , Shetty CR . Aortic stenosis. An atherosclerotic disease?J Heart Valve Disease1999; 8: 416 — 423 .
26.
Austin MA , Edwards KLSmall dense low density lipoproteins, insulin resistance syndrome and non-insulin dependent diabetes mellitus . Curr Opin Lipidology1996;7: 167 — 171 .
27.
Martini F , Farsi A , Gori AM et al. Antiphospholipid antibodies (aPL) increase potential monocyte procoagulant activity in patients with systemic lupus erythematosus . Lupus1996; 5: 206 — 211 .
28.
Leong KH , Koh ET , Feng PH , Boey ML . Lipid profiles in patients with systemic lupus erythematosus . J Rheumatol1994; 21: 1264 — 1267
29.
Wierzbicki AS , Reynolds TM , Crook MA et al. Lipid lowering therapy in patients with HIV infection . Lancet1998; 351: 1782-1782 .
30.
Ridker PM , Cushman M , Stampfer MJ et al. Inflammation,aspirin and the risk of cardiovascular disease in apparently healthy men . New Engl J Med1997; 336: 973 — 979 .
31.
Maseri A . Inflammation, atherosclerosis and ischemic events-exploring the hidden side of the moon . New Engl J Med1997; 336: 1014 — 1016 .
32.
Alexander RW . Inflammation and coronary artery disease . New Engl J Med1994; 331: 468 — 469
George J , Gilburd B , Langewitz P et al. b2-glycoprotein I containing immune complexes in lupus patients: association with thrombocytopenia and lipoprotein (a) levels . Lupus1999; 8: 116 — 120 .
35.
Shoenfeld Y , Harats D , George J . Atherosclerosis and the antiphospholipid syndrome: a link unraveled?Lupus1998; 7 (Suppl 1=2): S140—S143 .
36.
Meroni PL , del Papa N , Raschi E et al. b2-glycoprotein I as a ‘cofactor’ for antiphospholipid reactivity with endothelial cells . Lupus1998; 7 (Suppl 1=2): S44—S47 .
37.
Cuadrado MJ , Tinahones F , Camps MT et al. Antiphosphlipid anti-beta 2 glycoprotein-I and anti-oxidised LDL antibodies in antiphospholipid syndrome . Q J Med1998; 91: 619 — 626 .
38.
Mazzone M . Apolipoprotein E secretion by macrophages its potential physiological functionCurr Opin Lipidol1996; 7: 303 — 307
39.
von Eckardstein A . Cholesterol efflux from macrophages and other cells . Curr Opin Lipidol1996; 7: 308 — 319 .
40.
Mahley RW . Apolipoprotein E:cholesterol transport protein with an expanding role in cell biology . Science1988; 240: 622 — 630
41.
George J , Afek A , Gilburd B et al. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies . Lupus1997; 6: 723 — 729 .
42.
Ikeda Y , Fujimoto T , Ameno M et al. Relationship between lupus nephritis activity and the serum levels of soluble VCAM-1 . Lupus1998; 7: 347 — 354 .
43.
Ahmed E , Nitayanand S , Mustafa A et al. Anti-cardiolipin antibodies and circulating immune complexes in type I diabetes mellitus: increased prevalence and relation to vascular complications . Clin Exp Immunol1999; 115: 255 — 259 .
44.
HuIthe J , Wikstrand J , Lidell A et al. Antibody titers against oxidised LDL are not elevated in patients with familial hypercholesterolaemia . Arterioscier Thromb Vasc Biol1998; 18: 1203 — 1211 .
45.
Tertov VV , Sobenin IA , Orekhov AN et al. Characteristics of low density lipoprotein isolated from immune complexes . Atherosclerosis1996; 122: 191 — 199 .
46.
Ryan M , Owens D , Kilbride B et al. Antibodies to oxidized lipoproteins and their relationship to myocardial infarction . Q J Med1998; 91: 411 — 415 .
47.
Vaarala O . Atherosclerosis in SLE and Hughes syndrome . Lupus1997; 6: 489 — 490 .
48.
Uterman G . Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease inpatients with familial hypercholesterolaemia . New Engl J Med1990; 322: 1494 — 1499 .
49.
Schriner PJ , Heiss G , Tyroler HA et al. Race and gender differences in association with Lp(a) with carotid artery wall thickness: the Atherosclerosis Risk in Communities Study . Circulation1993; 87: 1107—1113 .
Grainger DJ , Metcalfe JC . Transforming growth factor-beta: the key to understanding lipoprotein (a)?Curr Opin Lipidol1995; 6: 81 — 85 .
52.
Kuller LH , Tracy RP , Shaten J , Meilahn EN . Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: multiple risk factor intervention trial . Am J Epidemiol1996; 144: 537 — 547 .
53.
Levenson J , Giral P , Razavian M et al. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors . Arterioscler Thromb Vasc Biol1995; 15: 1263 — 1268 .
54.
Rossen RD . HMG-CoA reductase inhibitors: a new class of anti-inflammatory drugs?J Am Coll Cardiol1997; 30: 1218 — 1219 .
55.
Rosenson RS , Tangney CC . Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction . JAMA1998; 279: 1643 — 1650 .
56.
Ridker PM , Rifai N , Pfeffer MA et al. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels . Circulation1998; 98: 839 — 844 .
57.
Luscher TF , Tanner PC , Noll G . Lipids and endothelial function: effects of lipid lowering and other therapeutic interventions . Curr Opin Lipidol1996; 7: 287 — 292 .
Vogel RA , Corretti MC , Gellman J . Cholesterol, cholesterol-lowering and endothelial function . Prog Cardiovasc Dis1998; 41: 117 — 136 .
60.
Pierangeli SS , Colden-Stanfield M , Liu X et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo . Circulation1999; 99: 1997 — 2002 .
Libby P , Ridker PM . Novel inflammatory markers of coronary risk . Circulation1999; 100; 1148 — 1150 .
63.
Williams KJ , Tabas I . Response to retention hypothesis of early atherogenesis . Arterioscier Thromb Vasc Biol1989; 9: 1 — 20 .
64.
Beisiegel U , St Clair RW . An emerging understanding of the interactions of plasma lipoproteins with the arterial wall that lead to the development of atherosclerosis . Curr Opin Lipidol1996; 7: 265 — 268 .
65.
Hang L , Stephens-Larsson P , Henry JP , Dixon FJ . The role of hypertension in the vascular disease and myocardial infarcts associated with murine systemic lupus erythematosus . Arthritis Rheum1983; 26: 1340 — 1345 .
66.
Galle J , Schnedier R , Heinloth A et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress . Kidney Intern1999; 55: 1450 — 1461 .
67.
Traub O , Berk BC . Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force . Arterioscier Thromb Vasc Biol1998; 18: 677 — 685 .
68.
Fellstrom B , Backmann U , Larrsson B , Wahlberg J . Accelerated atherosclerosis in the transplant recipient: role of hypertension . J Hum Hypertens1998; 12: 851 — 854 .
69.
Ginsburg KS , Liang MH , Newcomer L et al. Anti-phospholipid antibodies and the risk of ischemic stroke and venous thrombosis . Ann Intern Med1992; 117: 997 — 1002 .
70.
Brey RL , Hart RG , Sherman DG , Tegeler CH . Anti-phospholipid antibodies and cerebral ischaemia in young people . Neurology1990; 40: 1190 — 1196 .
71.
Kittner S , Gorelick P . Anti-phospholipid antibodies and stroke. An epidemiological perspective . Stroke1992; 23: 1 — 22 .
72.
Duell PB , Malinow MR . Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease . Curr Opin Lipidol1997; 8: 28 — 35 .
73.
Mehta RH , Eagle KA . Secondary prevention in acute myocardial infarction . Br Med J1998; 316: 838 — 842 .
74.
Bucher HG , Griffith LE , Guyatt GH . Systematic review on the risk and benefit of different cholesterol-lowering interventions . Arterioscier Thromb Vasc Biol1999; 19: 187 — 195 .
75.
Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study.(4S) . Lancet1994; 344: 1383 — 1389 .
76.
The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels . New Engl J Med1998; 339: 1349 — 1357 .
77.
Sachs FM , Pfeffer MA , Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels . New Engl J Med1996; 335: 1001 — 1009 .
78.
The Post-Coronary artery bypass graft trial investigators . The effect of aggressive cholesterol lowering of low-density lipoprotein cholesterol levels and low dose anti-coagulation on obstructive changes in saphenous vein coronary bypass grafts . New Engl J Med1997; 336: 153 — 162 .
79.
Rubins HB , Robins SJ , Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol . New Engl J Med1999; 341: 410 — 418 .
80.
Furberg CD . Natural statins and stroke risk . Circulation1999; 99: 185 — 188 .
81.
Shepherd J , Cobbe SM , Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia . New Engl J Med1996; 335: 153 — 162 .
82.
Downs JR , Clearfield M , Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of the Air Force-Texas Coronary artery prevention study . JAMA1998; 279: 1615—1622 .
83.
Vaughn CJ , Murphy MB , Buckley BM . Statins do more than just lower cholesterol . Lancet1996; 348: 1079 — 1082 .
84.
Waters D . Plaque stabilisation: a mechanism for the beneficial effect of lipid lowering therapies in angiography studies . Prog Cardiovasc Dis1994; 37: 107 — 120 .
85.
Wood D , Durrington PN , Poulter N et al. Joint British recommendations on prevention of coronary heart disease in clinical practice . Heart1999; 80 (Suppl 2): S1—S20 .
86.
Pyorala K , De Backer G , Poole-Wilson P , Wood D on behalf of the task force . Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension . Eur Heart J1994; 15: 1300— 1331 .
87.
Pyorala K , Wood D . Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced . Eur Heart J1998; 19: 1413 — 1415 .
88.
Fruchart JC , Brewer HB , Leitersdorf E . Consensus on the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease . Am J Cardiol1998; 81: 912 — 917 .
89.
Durrington PN , Illingworth R . Lipid lowering drugs: who gets what?Curr Opin Lipidol1998; 9: 289 — 294 .
90.
Nayak V , Esdaile JM . The efficacy of anti-malarials in systemic lupus erythematosus . Lupus1996; 5 (Suppl 1): S23—S27 .
